Radiation-induced neuroinflammation – a potential protective role for PARP (poly ADP ribose polymerase) inhibitors?

Rodrigo Gutierrez-Quintana, David J. Walker, Kaye J. Williams, Duncan M. Forster, Anthony J. Chalmers*

Institute of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow (RGQ, AJC, DJW); Division of Pharmacy and Optometry, School of Health Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester (KJW); Division of Informatics, Imaging and Data Sciences, Manchester Molecular Imaging Centre, Manchester, The University of Manchester (DMF).

*Corresponding Author: Anthony Chalmers; Wolfson Wohl Cancer Reperch Centre, Institute of Cancer Sciences, Garscube Estate, Glasgow, G61 1QH; Telephone: +44 (141) 3306426; Email: Anthony.Chalmers@Glasgow.ac.uk

DJW current affiliation is: School of Medicine, University of Dundee, DD1 9SY, UK.

Funding: Cancer Research UK (C16583/A28803; C147/A25254; C19941/A28701)

Conflict of interest: AJC and KJW have received research funding from AstraZeneca.

Authorship: RGQ, AJC and DJW wrote the manuscript; RGQ, AJW, KJW, DMF and DJW created the review concept, designed the structure and reviewed the manuscript.

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract:

Radiotherapy (RT) plays a fundamental role in the treatment of glioblastoma (GBM). GBM are notoriously invasive and harbour a subpopulation of cells with stem-like features which exhibit upregulation of the DNA damage response and are radioresistant. High radiation doses are therefore delivered to large brain volumes and are known to extend survival but also cause delayed toxicity with 50-90% of patients developing neurocognitive dysfunction. Emerging evidence identifies neuroinflammation as a critical mediator of the adverse effects of RT on cognitive function. In addition to its well-established role in promoting repair of radiation induced DNA damage, activation of poly(ADP-ribose) polymerase (PARP) can exacerbate neuroinflammation by promoting secretion of inflammatory mediators. Therefore, PARP represents an intriguing mechanistic link between radiation-induced activation of the DNA damage response and subsequent neuroinflammation. PARP inhibitors have emerged as promising new agents for GBM when given in combination with RT, with multiple preclinical studies demonstrating radiosensitizing effects and at least three compounds being evaluated in clinical trials. We propose that concomitant use of PARP inhibitors could reduce radiation-induced neuroinflammation and reduce the severity of radiation-induced cognitive dysfunction while at the same time improving tumour control by enhancing radiosensitivity.

Keywords: Radiation therapy; glioblastoma; neuroinflammation; neuroprotection; DNA damage; microglia.
Introduction

Radiotherapy (RT) plays a fundamental role in the treatment of patients with brain metastases and primary central nervous system (CNS) tumours, extending survival for many of these patients. Of the primary malignant brain tumours, glioblastoma (GBM) is the most common in adults and carries a very poor prognosis (median survival of 12-18 months). GBM are notoriously invasive, infiltrating the brain parenchyma extensively, so high doses of RT (typically 60 Gray (Gy)) are often delivered to large volumes of brain in order to delay recurrence and extend survival. The irradiated volume inevitably includes normal, functioning brain tissue and brain RT frequently causes devastating effects on brain function. They can be divided into acute, subacute and late effects, of which the late effects have the greatest impact. These arise months or even years after treatment and in many cases culminate in irreversible cognitive decline. While adverse neurocognitive effects of RT are common, the specific impact of radiotherapy on quality of life in long-term survivors of GBM has not been well characterised. Predicting the clinical impact of RT is complicated since both acute and late effects of RT on quality of life are context-dependent, being influenced by numerous radiobiological (RT dose, volume, timing and duration), physiological (pre-existing brain function) and patient related factors (age, sex, comorbidities). Although RT remains the most effective non-surgical treatment modality for GBM, its efficacy is confounded by the innate and adaptive radioresistance of these tumours which is reflected in their inevitable recurrence.

The fundamental rationale for using RT in cancer treatment is based on the rapidly proliferating phenotype of cancer cells which, in addition to defects in the DNA damage response, makes them sensitive to fractionated courses of radiation. RT damages cellular DNA by causing single strand (SSBs) and double strand breaks (DSBs). This initiates the DNA damage response (DDR), an intricate signalling network of proteins that interrupts cell cycle progression and facilitates DNA repair. Failure to repair DNA breaks can result in cell death either through apoptosis or via mitotic catastrophe, the former being more prevalent in non-malignant cells and the latter predominating in
cancer cells.² A critical sub-population of GBM cells that retains stem cell characteristics exhibits marked upregulation of the DDR, which renders them resistant to DNA damaging treatments including radiotherapy.³

Different cell populations within the normal brain also exhibit markedly different levels of radiation sensitivity. Neural stem cells and undifferentiated neural progenitor cells (NPCs) are highly radiosensitive, undergoing apoptosis, proliferative arrest and premature differentiation into other neural cell types in response to relatively low radiation doses.⁴ As such, it is hypothesized that the neurogenic niches in the brain are the most susceptible to radiation-induced DNA damage and play key roles in the pathogenesis of neurotoxicity and associated cognitive deficits.

Beyond this well documented phenomenon, the precise mechanisms of RT-induced neurotoxicity are still being investigated and appear to be multiple and complex. Recently emerging evidence cites radiation-induced neuroinflammation as a critical predictor of the long-term effects of RT on cognitive decline.⁵ Neuroinflammation is the inflammatory response within the CNS and is critical in the resolution of cellular damage and tissue injury upon exposure to a variety of noxious stimuli. The magnitude and duration of the neuroinflammatory response, and hence its functional impact, is strongly dependent upon the nature of the stimulus with potential for both positive (axonal regeneration, tissue repair) and negative effects (neuronal damage, cognitive impairment, anxiety/depression) on brain physiology and behaviour. In the context of brain RT, the general consensus is that radiation induces neuroinflammation through activation of microglia, astrocytes and endothelial cells in response to neural cell damage.⁵ The microglia-mediated neuroinflammation that ensues is similar in nature to that observed in a variety of neurological diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), cerebral ischemia, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).⁶

One of the hallmarks of both the DDR and neuroinflammation is activation of the poly(ADP-ribose) polymerase (PARP) family of proteins. PARP proteins are well characterized for their integral
role in the DDR, primarily initiating base excision repair (BER) in response to SSBs. Binding of PARP-1 to DNA breaks activates its catalytic function, which is to generate long, branching chains of poly(ADP-ribose) (PAR) on itself and a variety of target proteins. These modifications stimulate recruitment of BER-associated proteins and dissociation of PARP-1 from the damaged sites, promoting DNA repair and cell survival.\textsuperscript{7} To a lesser extent, PARP proteins also interact with kinases such as ataxia-telangiectasia mutated (ATM), nibrin (NBS1) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to mediate DSB repair through the homologous recombination (HR) and non-homologous end joining (NHEJ) repair pathways.\textsuperscript{7}

The mechanisms linking PARP activity to neuroinflammation are complex and less well characterized than its DDR functions. Accumulating evidence implicate PARP-mediated secretion of inflammatory mediators from damaged immune cells as the primary mechanism in multiple central nervous system diseases, including stroke, brain trauma and neurodegenerative processes.\textsuperscript{8–10} However, this role for PARP has not been studied in the context of radiation-induced neuroinflammation. PARP hyperactivation is implicated in several diseases sharing inflammatory/immune-mediated pathways including those associated with cancer progression and neurodegeneration.\textsuperscript{11} Therefore, PARP activity represents an intriguing mechanistic link between radiation-induced activation of the DDR and subsequent neuroinflammation.

Despite the relative lack of mechanistic understanding, there is extensive data showing that pharmacological inhibition or genetic depletion of PARP exerts beneficial effects by alleviating neuroinflammation in several animal models of inflammatory CNS conditions including stroke, traumatic brain injury, meningitis, and experimental autoimmune encephalomyelitis (EAE).\textsuperscript{12–15} Likewise, multiple studies in various preclinical tumour models have demonstrated that PARP inhibitors (PARPi) have modest but consistent radiosensitizing effects; indeed at least three PARPi are currently undergoing early phase clinical evaluation in a variety of cancer types including GBM.\textsuperscript{16} While PARPi have been found to exacerbate acute radiation toxicity in rapidly proliferating normal
tissues such as the oesophageal or oropharyngeal mucosa, early data indicate that they can be combined with brain radiotherapy without adverse effects. Utilizing PARPi in combination with brain RT offers the exciting prospect of sparing normal tissue from radiation-induced neuroinflammation whilst enhancing tumour responses to radiation. However, our current understanding of the suppressive effects of PARP inhibition on neuroinflammation is constrained by the over-reliance on the use of animal models harbouring PARP genetic defects (KO) and the relative lack of pharmacological PARPi capable of penetrating the brain parenchyma. PARPi utilized in clinical and preclinical studies block the enzymatic function of PARP by competing with its NAD+ substrate at the catalytic domain. This interferes with the DDR by suppressing BER function but also by preventing auto-modification of PARP thus delaying its release. This phenomenon of ‘PARP trapping’ is increasingly recognized as playing a key mechanistic role in the therapeutic effects of PARPi, and accounts for many of the differences observed between pharmacological inhibition and genetic depletion of PARP.

The aim of this review is to provide an overview of the physiological and clinical impact of radiation-induced neuroinflammation and the specific role of PARP enzymes in this response. Of the many PARP family proteins, PARP-1 is by far the most abundant, accounting for up to 90% of poly(ADP-ribosylation) in most cells studied to date. PARP-2 and PARP-3 are much less abundant but have been shown to make measurable contributions to the DDR. Most studies in the neuroinflammation field have focused on PARP-1. Of note, the vast majority of PARP inhibitors currently available are active against both PARP-1 and PARP-2. This review will focus primarily on the role of PARP-1 in the pathophysiology of radiation-induced neuroinflammation. We intend to emphasize the importance of PARP hyperactivation in neuroinflammation and discuss the clinical significance of PARP inhibitors both as radiosensitizing agents in GBM cells and as potential mitigators of radiation induced and inflammatory mediated neurotoxicity.
Neuroinflammatory response to ionizing radiation

The cellular and molecular mechanisms involved in radiation-induced brain injury and secondary cognitive dysfunction are beginning to be elucidated. Although vascular abnormalities, demyelination, NPC death, decreased neurogenesis and direct glial activation play important roles, recent studies have revealed that irradiation (IR) can trigger immune responses within the CNS, leading to chronic neuroinflammation. Neuroinflammation is a complex process, the nature and extent of which depend on the context, duration and anatomical location of the primary insult. Although the neuroinflammatory response has evolved to mitigate triggering factors in order to restore and maintain homeostasis, it can also be damaging and may result in adverse physiological, biochemical and behavioural consequences. This inappropriate response is not well understood but seems to be a consequence of the complex mechanisms controlling microglial activation in different brain regions.

The pathophysiology of the neuroinflammatory response to ionizing radiation involves primary structural damage and secondary effects on cell dysfunction that lead to progressive changes and associated cognitive decline long after the initial injury. For many years, neuroinflammation was considered a self-contained process, predominantly regulated by astrocytes and resident immune cells such as microglia; this contributed to the dogma that the CNS was an ‘immune-privileged’ organ. However, research in the last few years has clearly demonstrated that this is not the case. Neuroinflammation involves interplay between several resident CNS cell types and peripheral immune cells that migrate into the brain parenchyma through the blood brain barrier (BBB), the permeability of which is often compromised upon endothelial cell insult and subsequent activation. These discoveries have stimulated a comprehensive re-evaluation of neuroinflammatory responses in neurodegenerative diseases, traumatic brain injury and, to a lesser extent, the pathophysiology of radiation-induced brain injury.
It is well recognized that IR induces activation of microglia and endothelial cells which together initiate an inflammatory response within the CNS. Microglia can become activated by alarmins secreted by neurons and endothelial cells that have suffered radiation damage. One well-described example is high mobility group box 1 (HMGB1), expression of which is upregulated following IR exposure and thought to contribute to microglial activation by binding to the toll-like receptor 4 (TLR4). Another possible mechanism for microglial activation is by direct IR-induced DNA damage causing modification of transcription factors such as nuclear factor κB (NFκB) and activating protein 1 (AP-1), which control expression of several genes involved in initiating the inflammatory cascade. This is followed by a surge in inflammatory mediators consisting of cytokines, chemokines and reactive oxygen species (ROS), which are produced by microglia and astrocytes. These secretions promote microglial phagocytosis of damaged neural cells and particulate matter, resulting in increased neuronal and progenitor cell death. Inflammatory mediators secreted by microglia and astrocytes, such as interleukin-6 (IL-6), stimulate the endothelium to increase expression of adhesion molecules on the luminal surface, such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1), compromising BBB integrity. Brain microvascular endothelial cells can also be directly activated by IR, increasing expression of adhesion molecules. Leukocytes then attach to endothelial cells and, together with microglia, secrete a panel of matrix metalloproteinases (MMPs) that destabilize the parenchymal basement membrane, enabling leukocyte migration across the BBB and perivascular spaces into the brain parenchyma to further aggravate neuroinflammation. Alarmins, such as HMGB1, also contribute to radiation-induced endothelial barrier injury by activation of the mitogen-activated protein kinase (MAPK) signalling pathway. Among chemokines, CCL2 allows infiltration of peripheral macrophages, altering the brain microenvironment and playing a prominent role in the development of radiation induced cognitive alterations (Figure 1).

Microglial activation can persist for months after IR, creating a chronic and self-sustaining neuroinflammatory process characterized by a vicious cycle of microglial activation, secretion of pro-
inflammatory agents, neuronal damage and cell death. Recently, it has been found that age at the time of IR has an important impact on chronic microglial activation. Using single cell RNA-sequencing, researchers demonstrated that adult mice developed persistent microglial activation after brain irradiation, whereas juvenile mice (3 weeks old) exhibited an initial dynamic activation microglia that was followed by significant recovery after one week. This observation is in keeping with extensive clinical data showing that elderly patients are at increased risk of chronic radiation induced neurotoxicity.

More specifically, neuroinflammation in the hippocampus has been shown to influence the functional integration of hippocampal neurons. Radiation-induced neuroinflammation disrupts microvascular niches in mouse models, depleting neurogenesis and causing long-term cognitive deficits such as memory loss. These and other studies have identified that selective inhibition of microglia-mediated neuroinflammation was able to ameliorate radiation-induced cognitive impairment, making it an interesting therapeutic target.

**PARP activity in neuroinflammation**

PARP-1 is best known for its participation in DNA repair processes, where it is involved chiefly in BER. It also plays a role in alternative NHEJ, which is thought to act as a backup pathway in cells deficient in canonical NHEJ, and interacts with the HR pathway both directly and indirectly via its role in maintenance of DNA replication fork stability. PARP also contributes to a wide range of cellular and biochemical pathways (reviewed in Weaver et al.) with increasing evidence indicating a critical role in modulating the inflammatory response both within and without the CNS.

The most established pathway through which PARP-1 promotes neuroinflammation is via regulation of pro-inflammatory transcription factors such as NFκB, AP-1 and nuclear factor of activated T-cells (NFAT). NFκB is one of the best characterized transcription factors, regulating the
expression of multiple genes involved in immunity and inflammation. Under basal conditions, NFκB is localised in the cytoplasm, but once activated it undergoes nuclear translocation allowing DNA binding and increased transcription of inflammatory cytokines, chemokines, adhesion molecules and inflammatory mediators including inducible nitric oxide synthase (iNOS), ROS and tumour necrosis factor α (TNFα). Several studies have reported that nuclear translocation of NFκB requires PARP-1 function. Following radiation induced DNA damage, PARP binds to SSBs and recruits BER proteins to induce PARylation and initiate DNA repair. During this process, PARP undergoes automodification which promotes its disassociation from DNA and enables it to form a stable nucleoplasmic protein complex comprised of SUMO1, P1ASγ, NEMO (IKKγ) and ATM. ATM mediated phosphorylation of NEMO triggers sumoylation of the inactive NFκB complex in the cytoplasm and subsequent ubiquitination of NEMO from the activated complex. In the nucleus, PARP physically binds to the p65/p50 subunits through p300-CBP histone acetyltransferase, allowing NFκB driven transcription of pro-inflammatory molecules (Figure 2).

In vitro and in vivo studies have shown that the response of microglia and astrocytes to inflammation is mediated by PARP-1 and its activation stimulates protein synthesis and proliferation. Microglial activation in response to several stimuli including cytokines (e.g. TNFα), and alarmins (e.g. S100β and HMGB1) is regulated by PARP-1. PARP-1 can be activated by DNA damage, usually secondary to reactive oxygen and nitrogen species (ROS/RNS), but also in response to ERK1/2-mediated phosphorylation as a consequence of raised intracellular Ca²⁺.

BBB dysfunction is also widely observed in neuroinflammatory-associated diseases. PARP-1 activity is heavily implicated in this phenomenon, with several studies citing associations between PARP activation, oedema formation and increased infiltration of peripheral immune cells into the brain parenchyma. Although the exact mechanisms are unclear, it has been proposed that PARP upregulates matrix metalloproteinase-9 (MMP-9) which digests tight junctions and basement membrane proteins, contributing to BBB disruption. PARP-mediated inflammation also increases
the expression of adhesion molecules controlling leukocyte migration across the BBB.\textsuperscript{45} Interestingly, PARP activation in monocytes promotes their adhesion to the brain microvascular endothelium and subsequent migration across the BBB by promoting cytoskeletal rearrangements.\textsuperscript{46} PARP-1 also regulates microglia mediated control of endothelial tight junction integrity influencing BBB permeability.\textsuperscript{48}

Finally, PARP-1 is a key mediator of neuronal cell death associated with excitotoxicity, ischemia and oxidative stress. Hyperactivation of PARP-1 can lead to energy failure due to consumption of nicotinamide adenine dinucleotide (NAD+) followed by adenosine triphosphate (ATP) depletion that results in cell death and necrosis, promoting further microglia activation.\textsuperscript{9} At the same time, excessive PARP-1 activation also leads to PAR accumulation in the cytoplasm, translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus and cell death by parthanatos, which is a specific form of cell death that occurs as a result of overactivation of PARP-1.\textsuperscript{49}

**PARP inhibitors as anti-inflammatory agents**

As previously mentioned, hyperactivation of PARP can be detrimental, causing neuronal death as well as chronic microglial activation and neuroinflammation. These observations led to the evaluation of PARP inhibitors (PARPi) as potential mitigators of neurotoxicity in animal models of CNS pathologies in which neuroinflammation plays a key role.

Many studies have empirically demonstrated protective effects of various PARPi in rodent and primate models of stroke.\textsuperscript{50–57} Ischaemia followed by reperfusion appears to be a potent stimulus of PARP overactivation which results in neuronal death, as described above.\textsuperscript{56,57} In addition to reducing necrosis and apoptosis in stroke models, inhibition of PARP has been reported to reduce
inflammation, astrogliosis and microglia activation.\textsuperscript{8,58,59} PARP inhibition decreases pro-inflammatory cytokines such as interferon gamma (IFN\(\gamma\)), TNF\(\alpha\), IL-6 and IL-17 and increases anti-inflammatory cytokines such as IL-4, IL-10 and transforming growth factor beta 1 (TGF\(\beta\)1).\textsuperscript{60,61} It also reduces the levels of transcription factors such as NF\(\kappa\)B and inflammatory prostaglandins such as cyclooxygenase 2 (COX-2).\textsuperscript{47,61} Regulatory T cells (Tregs) play a modulatory role in immune responses and can improve outcomes after ischemic strokes. One recent study showed that PARP inhibition upregulates circulating Treg cells, which could help alleviate neuroinflammation by altering cytokine levels.\textsuperscript{60} PARP inhibition has also been shown to protect the vasculature and decrease BBB damage by down-regulating VCAM-1, ICAM-1, E-selectin and MMP-9 expression and reducing extravasation of immunoglobulins.\textsuperscript{47,50,61–63}

The neuroprotective properties of PARPi have also been extensively studied in animal models of traumatic brain injury.\textsuperscript{9,13,15,64–70} ROS/RNS produced after the initial trauma cause upregulation of PARP activity leading to secondary additional neuronal injury which can be reversed by PARP inhibition.\textsuperscript{69,71} Apart from the attenuation of early neuronal injury, PARP inhibition in brain trauma models also reduces microglial activation and reactive astrogliosis in rodent and pig (\textit{Sus scrofa}) models.\textsuperscript{9,15,72} As in stroke models, it has been shown that PARP inhibition decreases levels of NF\(\kappa\)B in the cortex, reducing inflammation and downregulating MMP-9 thus preserving BBB function.\textsuperscript{13,64}

The role of PARP in neuroinflammatory disease has also been studied in MS and its preclinical model experimental allergic encephalomyelitis (EAE), as well as bacterial meningitis.\textsuperscript{73–77} PARP inhibition attenuated oligodendrocyte depletion and decreased demyelination in a rodent model that uses cuprizone.\textsuperscript{74} Of direct clinical relevance, high PARP-1 expression has been identified in blood leukocytes from patients with MS and PARP inhibition was associated with decreased expression of factors such as TGFBR1/TGFBR2/BCL6 in B cells.\textsuperscript{73} As in stroke models, the immunomodulatory effects of PARP inhibitors appear to involve both increased numbers of Tregs
and enhanced function.\textsuperscript{76} Consistent with these findings, expression of ICAM-1, NFκB and the inflammatory mediators interferon-γ, TNFα, and iNOS were decreased in CNS tissues from rodent models treated with PARP inhibitors.\textsuperscript{75,76}

Evidence supporting important pathogenic roles for PARP-1 now extends to neurodegenerative diseases, in which it has been observed to promote neuronal cell death, mitochondrial function and neuroinflammation. Preclinical studies have shown therapeutic benefits of a variety of PARPi in rodent models of PD, AD and Huntington’s disease (HD).\textsuperscript{78–82} Reduced microglial activation in response to PARP inhibition has been reported in all these diseases.\textsuperscript{78,80,82}

Much less evidence is available in the context of radiation-induced neuroinflammation. However, the intracellular mechanisms implicated in this phenomenon share many of the same signalling pathways as the CNS diseases described above, and there is a prominent inflammatory component. As described earlier, radiation has been shown to regulate NFκB transcription factors in the brain, causing microglial activation and increasing transcription of inflammatory cytokines, chemokines, adhesion molecules and inflammatory mediators including iNOS, ROS and TNFα. All these factors are implicated in the many neurological conditions in which PARP inhibition has shown promising results. In this context, it seems entirely reasonable to propose that PARP inhibition could play a neuroprotective role in suppressing radiation-induced neuroinflammation and thus reducing the associated cognitive decline.

**Widening the therapeutic ratio by combining PARP inhibitors with radiation**

As previously mentioned, PARP-1 plays an important role in DNA damage repair, predominantly by stimulating and facilitating function of the BER pathway, and with additional roles in alternative NHEJ, HR and replication fork restart.\textsuperscript{83,84} In keeping with these roles, PARP inhibition causes accumulation of DNA breaks in replicating cells and PARPi have potent single agent activity
against cells harbouring defects in HR repair.\textsuperscript{85} Of greater relevance to their potential roles in neuro-oncology, PARPi also exhibit potentiating effects when combined with DNA damaging agents such as TMZ and RT, which together form ‘standard of care’ for GBM patients. Multiple studies in pre-clinical models have demonstrated that PARPi potently augment the cytotoxic effects of TMZ and consistently enhance radiosensitivity across a broad range of cancer types including GBM. Importantly, these radiosensitizing effects are only observed in proliferating cells, in which unresolved SSBs are converted into DSBs during replication, thus enhancing the cytotoxic effects of radiation.\textsuperscript{86} In the context of GBM, therefore, PARP inhibition is predicted to enhance the capacity of radiotherapy to ablate rapidly proliferating tumour cells while having minimal effect on cells in the surrounding normal brain, which are almost exclusively non-replicating.

Until recently, one of the main limitations to evaluating PARPi in the treatment of brain tumours concerns their ability to penetrate the BBB. Some newly developed PARPi such as pamiparib (BeiGene) and niraparib (Zejula\textsuperscript{®}, Tesaro) have shown improved BBB penetration in mice, making them attractive options.\textsuperscript{87,88} However, a recent phase I clinical trial reported that olaparib (Lynparza\textsuperscript{®}, AstraZeneca) penetrates both tumour core and margin regions in patients with recurrent GBM, despite failing to penetrate the BBB of mice and rats. These findings support the concept that the BBB is sufficiently disrupted in and adjacent to GBM that even ‘non-brain penetrant’ PARPi may have clinical activity.\textsuperscript{89}

Several studies using different PARPi provide strong evidence of radiosensitizing activity both \textit{in vitro} and \textit{in vivo} in a variety of pre-clinical models of adult and paediatric glioma.\textsuperscript{86,90–94} The radiosensitizing effects of PARP inhibitors have also been reported in other CNS tumours such as medulloblastoma and ependymoma.\textsuperscript{90}

These pre-clinical data underpin multiple phase I/II clinical trials that have been completed or are actively recruiting, evaluating three different PARPi (olaparib (Lynparza\textsuperscript{®}, AstraZeneca), veliparib (AbbVie) and pamiparib (BeiGene)) in combination with radiotherapy and/or TMZ in
patients with gliomas, predominantly but not exclusively GBM. A comprehensive list of the current clinical trials can be found in a recent review.\textsuperscript{16}

Taking all this clinical and pre-clinical together, we propose that the strategy of combining RT and PARP inhibition for the treatment of GBM holds exceptional promise for this cancer of extreme unmet need. Tumour cell death will be enhanced by inhibition of DNA repair pathways, whilst normal brain tissue may be protected both from radiation induced neuroinflammation, via suppression of glial activation and inflammatory mediators, and from radiation driven apoptosis of NPCs and neurons, via avoidance of ATP depletion (Figure 3).

Having made this proposal, we would also like to acknowledge the crucial role played by the tumour microenvironment in influencing treatment responses of GBM and other brain tumours, and the additional layers of complexity that this creates. Tumour-associated macrophages and microglia have been shown to play an important role in creating an immunosuppressive tumour environment that protects tumour cells from recognition and destruction by the immune system.\textsuperscript{95} While one might speculate that PARP inhibition would further suppress microglial activity, thus protecting tumour cells, a recent abstract described the opposite effect.\textsuperscript{96} This illustrates the importance of assessing the neuroinflammatory effects of PARP inhibition in microenvironments that recapitulate the clinical scenario. More specifically, the presence of a tumour might alter the immunomodulatory effects of both radiation and PARP inhibition. Adding further complexity, combining DNA damaging agents such as radiation with PARPi has potential to enhance the immunogenicity of the tumour cells by promoting neoantigen release, increasing tumour mutational burden, and enhancing immunogenic signalling via the cGAS-STING pathway.\textsuperscript{97}

Considering these complex interactions, we would like to emphasise the urgent need to develop new, orthotopic, immunocompetent models of GBM that would allow detailed study of the multifaceted effects of PARP inhibition and their consequences on cell survival, neuroinflammation and cognition in the context of a tumour bearing brain with an intact immune system.
While this review focuses on PARP, it is important to mention that other proteins of the DDR pathway, including ATM, ataxia telangiectasia and Rad3-related protein (ATR) and checkpoint kinase 1 (CHK1) have also shown radiosensitizing effects in preclinical models of GBM.\textsuperscript{98,99} ATM inhibitors are potent tumour radiosensitizers that are currently being evaluated in clinical trials in GBM patients; they may have neuroprotective effects by modulating oxidative stress and preventing neuronal apoptosis.\textsuperscript{98,100} ATR and CHK1 exert modest radiosensitizing effects similar to PARP inhibitors.\textsuperscript{98} Neither ATM, ATR nor CHK1 inhibitors have been shown to regulate neuroinflammation.

Conclusions

Although, our understanding of the pathophysiology of radiation induced cognitive dysfunction is currently limited, there is strong evidence supporting a major role of neuroinflammation. Recent data have identified neuroinflammation as a common feature in many CNS diseases including brain trauma, stroke and multiple neurodegenerative processes, and preclinical studies have provided robust evidence to support the use of PARPi to alleviate neuroinflammation in these conditions. At the same time the use of PARPi as radiosensitizers for the treatment of brain tumours has generated promising pre-clinical data and multiple early phase clinical trials are ongoing. This, in combination with the availability of brain penetrant PARPi, offers the intriguing opportunity to radiosensitize brain tumour cells, while simultaneously reducing radiation induced neuroinflammation. The translation of these exciting preclinical findings to the clinic offers the promise of improving survival and quality of life for brain tumour patients receiving radiotherapy. It will be important to include neuroinflammatory markers, cognitive function scores and quality of life measures when designing future clinical trials, to help elucidate the potential neuroprotective role of PARPi when combined with radiation.
Funding

Cancer Research UK (C16583/A28803; C147/A25254; C19941/A28701)
References

1. Walker MD, Green SB, Byar DP, et al. Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery. N Engl J Med. 1980;303(23):1323-1329.

2. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071-1078.

3. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.

4. Barazzuol L, Hopkins SR, Ju L, Jeggo PA. Distinct response of adult neural stem cells to low versus high dose ionising radiation. DNA Repair (Amst). 2019;76:70-75.

5. Lumniczky K, Szatmári T, Sáfrány G. Ionizing radiation-induced immune and inflammatory reactions in the brain. Front Immunol. 2017;8(MAY).

6. Subhramanyam CS, Wang C, Hu Q, Dheen ST. Microglia-mediated neuroinflammation in neurodegenerative diseases, Semin Cell Dev Biol. 2019;94:112-120.

7. Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610-621.

8. Chen J, Li X, Xu S, et al. Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities. Front Cell Neurosci. 2020;14.

9. Stoica BA, Loane DJ, Zhao Z, et al. PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. J Neurotrauma. 2014;31(8):758-772.

10. Kauppinen TM, Suh SW, Higashi Y, et al. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β. J Neuroinflammation. 2011;8.
11. Dörsam B, Seiwert N, Foersch S, et al. PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A. 2018;115(17):E4061–E4070.

12. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol. 2009;10(9):958-964.

13. Lescot T, Fulla-Oller L, Palmier B, et al. Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood-brain barrier permeability and edema formation after focal traumatic brain injury in rats. J Neurotrauma. 2010;27(6):1069-1079.

14. Kauppinen TM, Swanson RA. Poly(ADP-Ribose) Polymerase-1 Promotes Microglial Activation, Proliferation, and Matrix Metalloproteinase-9-Mediated Neuron Death. J Immunol. 2005;174(4):2288-2296.

15. D’Avila JC, Lam TI, Bingham D, et al. Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflammation. 2012;9.

16. Ning J, Wakimoto H. Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends in Cancer. 2020;6(2):147-159.

17. Karam SD, Reddy K, Blatchford PJ, et al. Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer. Clin Cancer Res. 2018;24(20):4949-4959.

18. Chabot P, Hsia T-C, Ryu J-S, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol. 2017;131(1):105-115.

19. Baxter PA, Su JM, Onar-Thomas A, et al. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: A Pediatric Brain
Tumor Consortium study. Neuro Oncol. 2020;22(6):875-885.

20. Murai J, Huang SYN, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588-5599.

21. Kalm M, Fukuda A, Fukuda H, et al. Transient inflammation in neurogenic regions after irradiation of the developing brain. Radiat Res. 2009;171(1):66-76.

22. Zhou H, Jin C, Cui L, et al. HMGB1 contributes to the irradiation-induced endothelial barrier injury through receptor for advanced glycation endproducts (RAGE). J Cell Physiol. 2018;233(9):6714-6721.

23. Xue J, Dong JH, Huang GD, Qu XF, Wu G, Dong XR. NF-κB signaling modulates radiation-induced microglial activation. Oncol Rep. 2014;31(6):2555-2560.

24. Lécuyer MA, Kebir H, Prat A. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta - Mol Basis Dis. 2016;1862(3):472-482.

25. Rom S, Zuluaga-Ramirez V, Reichenbach NL, et al. PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. J Neuroinflammation. 2016;13(1).

26. Morganti JM, Jopson TD, Liu S, Gupta N, Rosi S. Cranial irradiation alters the brain’s microenvironment and permits CCR2+ macrophage infiltration. PLoS One. 2014;9(4).

27. Jenrow KA, Brown SL, Lapanowski K, Naei H, Kolozsvary A, Kim JH. Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment. Radiat Res. 2013;179(5):549-556.

28. Li MD, Burns TC, Kumar S, Morgan AA, Sloan SA, Palmer TD. Aging-like changes in the transcriptome of irradiated microglia. Glia. 2015;63(5):754-767.

29. Osman AM, Sun Y, Burns TC, et al. Radiation Triggers a Dynamic Sequence of Transient
Microglial Alterations in Juvenile Brain. Cell Rep. 2020;31(9).

30. Saito K, Mukasa A, Narita Y, et al. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: A retrospective study. Neurol Med Chir (Tokyo). 2014;54(4):272-279.

31. Monje ML, Toda H, Palmer TD. Inflammatory Blockade Restores Adult Hippocampal Neurogenesis. Science (80-. ). 2003;302(5651):1760-1765.

32. Weaver AN, Yang ES. Beyond DNA repair: Additional functions of PARP-1 in cancer. Front Oncol. 2013;3 NOV:290.

33. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-κB-driven transcription and microglial activation: Implication for neurodegenerative disorders. J Neurochem. 2003;85(2):306-317.

34. Raghunatha P, Vosoughi A, Kauppinen TM, Jackson MF. Microglial NMDA receptors drive pro-inflammatory responses via PARP-1/TRMP2 signaling. Glia. 2020;68(7):1421-1434.

35. Oliver FJ, Ménilisier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999;18(16):4446-4454.

36. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance. Oncogene. 2009;28(6):832-842.

37. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. Mol Cell. 2010;40(1):63-74.

38. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A Nuclear Poly(ADP-Ribose)-Dependent Signalosome Confers DNA Damage-Induced IκB Kinase Activation. Mol
39. Hassa PO, Haenni SS, Buerki C, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-κB-dependent transcription. J Biol Chem. 2005;280(49):40450-40464.

40. Martínez-Zamudio RI, Ha HC. PARP1 enhances inflammatory cytokine expression by alteration of promoter chromatin structure in microglia. Brain Behav. 2014;4(4):552-565.

41. Ullrich O, Diestel A, Eyüpoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol. 2001;3(12):1035-1042.

42. Vuong B, Hogan-Cann ADJ, Alano CC, et al. NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1. J Neuroinflammation. 2015;12(1).

43. Xu J, Wang H, Won SJ, Basu J, Kapfhamer D, Swanson RA. Microglial activation induced by the alarmin S100B is regulated by poly(ADP-ribose) polymerase-1. Glia. 2016;64(11):1869-1878.

44. Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, Swanson RA. Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated 1/2. Proc Natl Acad Sci U S A. 2006;103(18):7136-7141.

45. Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, Ramirez SH, Persidsky Y. Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions. J Cereb Blood Flow Metab. 2015;35(1):28-36.

46. Wu XL, Wang P, Liu YH, Xue YX. Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson’s disease. J Mol Neurosci. 2014;53(1):1-9.

47. Koh SH, Chang D II, Kim HT, et al. Effect of 3-aminobenzamide, PARP inhibitor, on matrix
metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology. 2005;214(1-2):131-139.

48. Mehrabadi AR, Korolainen MA, Odero G, Miller DW, Kauppinen TM. Poly(ADP-ribose) polymerase-1 regulates microglia mediated decrease of endothelial tight junction integrity. Neurochem Int. 2017;108:266-271.

49. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (80- ). 2002;297(5579):259-263.

50. El Amki M, Lerouet D, Garraud M, et al. Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice. Mol Neurobiol. 2018;55(12):9156-9168.

51. Kim Y, Kim YS, Kim HY, et al. Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke. Mol Neurobiol. 2018;55(9):7153-7163.

52. Moroni F, Chiarugi A. Post-ischemic brain damage: Targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J. 2009;276(1):36-45.

53. Abdelkarim GE, Gertz K, Harms C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001;7(3):255-260.

54. Greco R, Tassorelli C, Stefania Mangione A, et al. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. Eur J Pharmacol. 2014;744:91-97.

55. Moroni F, Cozzi A, Chiarugi A, et al. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. Br J Pharmacol. 2012;165(5):1487-1500.
56. Ding Y, Zhou Y, Lai Q, Li J, Gordon V, Diaz FG. Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment. Brain Res. 2001;915(2):210-217.

57. Egi Y, Matsuura S, Maruyama T, Fujio M, Yuki S, Akira T. Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia. Brain Res. 2011;1389:169-176.

58. Hamby AM, Suh SW, Kauppinen TM, Swanson RA. Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion. In: Stroke. Vol 38. Stroke; 2007:632-636.

59. Kauppinen TM, Suh SW, Berman AE, Hamby AM, Swanson RA. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab. 2009;29(4):820-829.

60. Noh MY, Lee WM, Lee SJ, Kim HY, Kim SH, Kim YS. Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients. Int Immunopharmacol. 2018;60:104-110.

61. Koh SH, Park Y, Chi WS, et al. The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur J Neurosci. 2004;20(6):1461-1472.

62. Teng F, Zhu L, Su J, et al. Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia. Neurochem Res. 2016;41(7):1516-1526.

63. Haddad M, Rhinn H, Bloqueil C, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol. 2006;149(1):23-30.

64. Tao X, Chen X, Hao S, et al. Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice. Neuroscience.
65. Clark RSB, Vagni VA, Nathaniel PD, Jenkins LW, Dixon CE, Szabó C. Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J Neurotrauma. 2007;24(8):1399-1405.

66. Besson VC, Croci N, Boulu RG, Plotkine M, Marchand-Verrecchia C. Deleterious poly(ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat. Brain Res. 2003;989(1):58-66.

67. Lai Y, Chen Y, Watkins SC, et al. Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury. J Neurochem. 2008;104(6):1700-1711.

68. Kövesdi E, Bukovics P, Besson V, et al. A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study. Int J Mol Sci. 2010;11(4):1253-1268.

69. Satchell MA, Zhang X, Kochanek PM, et al. A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3γ. J Neurochem. 2003;85(3):697-708.

70. Besson VC, Zsengellér Z, Plotkine M, Szabó C, Marchand-Verrecchia C. Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat. Brain Res. 2005;1041(2):149-156.

71. Hortobágyi T, Görlach C, Benyó Z, et al. Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: Neuroprotection by 3-aminobenzamide. Neuroscience. 2003;121(4):983-990.

72. Irvine KA, Bishop RK, Won SJ, et al. Effects of veliparib on microglial activation and functional outcomes after traumatic brain injury in the rat and pig. J Neurotrauma. 2018;35(7):918-929.
73. Meira M, Sievers C, Hoffmann F, et al. PARP-1 deregulation in multiple sclerosis. Mult Scler J - Exp Transl Clin. 2019;5(4):205521731989460.

74. Veto S, Acs P, Bauer J, et al. Inhibiting poly(ADP-ribose) polymerase: A potential therapy against oligodendrocyte death. Brain. 2010;133(3):822-834.

75. Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler J. 2011;17(7):794-807.

76. Scott GS, Kean RB, Mikheeva T, et al. The therapeutic effects of PJ34: [N-(6-Oxo-5,6-di hydrophenanthridin-2-yl)-N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther. 2004;310(3):1053-1061.

77. Park WS, Chang YS, Lee M. 3-Aminobenzamide, a poly (ADP-ribose) synthetase inhibitor, attenuates the acute inflammatory responses and brain injury in experimental Escherichia coli meningitis in the newborn piglet. Neurol Res. 2001;23(4):410-416.

78. Correani V, Martire S, Mignogna G, et al. Poly(ADP-riboseylated) proteins in β-amyloid peptide-stimulated microglial cells. Biochem Pharmacol. 2019;167:50-57.

79. Cosi C, Marien M. Implication of poly(ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism: Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. In: Annals of the New York Academy of Sciences. Vol 890. New York Academy of Sciences; 1999:227-239.

80. Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T. Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res. 2010;88(7):1522-1536.

81. Kam TI, Mao X, Park H, et al. Poly(ADP-ribose) drives pathologic a-synuclein
neurodegeneration in Parkinson’s disease. Science (80- ). 2018;362(6414).

82. Cardinale A, Paldino E, Giampà C, Bernardi G, Fusco FR. PARP-1 inhibition is neuroprotective in the R6/2 mouse model of huntington’s disease. PLoS One. 2015;10(8).

83. Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res. 2010;38(18):6065-6077.

84. Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 2006;25(6):1305-1314.

85. Fong PC, Boss DS, Yap TA, et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med. 2009;361(2):123-134.

86. Dungey FA, Löser DA, Chalmers AJ. Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential. Int J Radiat Oncol Biol Phys. 2008;72(4):1188-1197.

87. Xiong Y, Guo Y, Liu Y, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia (United States). 2020;22(9):431-440.

88. Sun K, Mikule K, Wang Z, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080-37096.

89. Hanna C, Kurian KM, Williams K, et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. Published online April 29, 2020.

90. van Vuurden DG, Hulleman E, Meijer OLM, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011;2(12):984-
996.

91. Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther. 2009;8(8):2243-2254.

92. Russo AL, Kwon HC, Burgan WE, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res. 2009;15(2):607-612.

93. Barazzuol L, Jena R, Burnet NG, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013;8(1).

94. Venere M, Hamerlik P, Wu Q, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014;21(2):258-269.

95. Ma Q, Long W, Xing C, et al. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Front Immunol. 2018;9:2924.

96. Sinha A, Katyal S, Kauppinen T. Abstract B33: PARP-dependent co-modulation of DNA repair and microglial activity as a dual-pronged anti-glioblastoma treatment strategy. In: Molecular Cancer Research. Vol 15. American Association for Cancer Research (AACR); 2017:B33-B33.

97. Reisländer T, Lombardi EP, Groelly FJ, et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun. 2019;10(1).

98. Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C, Chalmers AJ. Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res. 2015;75(20):4416-4428.
99. Patties I, Kallendrusch S, Böhme L, et al. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment. J Exp Clin Cancer Res. 2019;38(1).

100. Camins A, Verdaguer E, Folch J, Beas-Zarate C, Canudas A, Pallas M. Inhibition of Ataxia Telangiectasia-p53-E2F-1 Pathway in Neurons as a Target for the Prevention of Neuronal Apoptosis. Curr Drug Metab. 2007;8(7):709-715.
Captions:

**Figure 1:** Overview of the impact of ionizing radiation on key CNS cell populations. In response to cellular damage caused by IR, neurons and endothelial cells secrete alarmin molecules (e.g. HMGB1) which trigger microglial activation, while radiation-induced DNA damage within microglia themselves also promotes their activation. Pro-inflammatory molecules secreted by activated microglia, such as IL-6 and TNF-α, can prevent neural stem cell differentiation, impacting on neurogenesis and astrocyte development. Inflammatory mediators also stimulate increased expression of endothelial adhesion markers such as ICAM1 and P-selectin, leading to permeabilization of the blood brain barrier (BBB) and infiltration of peripheral immune cells into the brain parenchyma. This is further enhanced by the secretion of chemoattractant molecules (CCL2) by activated microglia.

**Figure 2:** PARP-mediated neuroinflammation in microglia. Following radiation induced DNA damage, PARP binds to SSBs and recruits BER proteins to induce PARylation and initiate DNA repair. During this process, PARP undergoes automodification which promotes its disassociation from DNA and enables it to form a stable nucleoplasmic protein complex comprised of SUMO1, P1ASγ, NEMO (IKKγ) and ATM. ATM mediated phosphorylation of NEMO triggers sumoylation of the inactive NF-κB complex in the cytoplasm and subsequent ubiquitination of NEMO from the activated complex. In the nucleus, PARP physically binds to the p65/p50 subunits through p300-CBP histone acetyltransferase, allowing NF-κB driven transcription of pro-inflammatory molecules. Unsustainable levels of inflammatory gene expression can lead to reciprocal increases in DNA damage, causing a positive feedback loop that further activates PARP and NF-κB, exacerbating oxidative stress and neuroinflammation.
Figure 3. Differential impact of radiation exposure +/- PARP inhibition in tumour and normal brain.

A. In tumour cells, PARP binds to DNA SSB in glioma cells and through the recruitment of BER proteins, facilitates DNA repair. B. PARP inhibitors compete with NAD+ at the PARP catalytic domain causing inhibition of PARP catalytic activity and the accumulation of unrepaired SSBs. This leads to the formation of DSBs, increased genomic instability and cell death. C. In the normal brain, radiation-induced DNA damage and the associated increase in PARP hyperactivity through interaction with NF-κB results in neuroinflammation, leading to reciprocal DNA damage and neural cell death. Hyperactivation of PARP and neuroinflammation can also exacerbate PARP-dependent cell death through the nuclear transfer of AIF from mitochondria, leading to apoptotic cell death of neurogenic cells contributing to cognitive decline. D. PARP inhibitors prevent PARP activation and PARP’s interaction with NF-κB, causing a reduction in the expression of inflammatory mediators and a reduction in neuroinflammation. Additionally, reduced PARP activation mitigates the onset of PARP-dependent cell death of neuronal cells.
Figure 2
Figure 3

A) Tumor

B) DNA damage + FASR + DNA damage

C) 'Normal Brain'

D) Preserved cognitive function